Gallium-68-Labeled Prostate-Specific Membrane Antigen-11 PET/CT of Prostate and Nonprostate Cancers.
AJR Am J Roentgenol. 2019 Aug;213(2):286-299. doi: 10.2214/AJR.19.21084. Epub 2019 Jun 5.
Osmany S, Zaheer S, Bartel TB, Johnston M, Peh WM, Barmaky S, Jadvar H.
OBJECTIVE. The purpose of this study is to provide a concise summary of the current experience with 68Ga-labeled prostate-specific membrane antigen (PSMA)-11 imaging of prostate and nonprostate malignancies and benign conditions.
CONCLUSION. PSMA is overexpressed in prostate cancer and in the neovasculature of many other malignancies. The relevance of PSMA as a biologic target, coupled with advances in the design, synthesis, and evaluation of PSMA-based radionuclides for imaging and therapy, is anticipated to play a major role in patient care.
Read Full Article Here: https://doi.org/10.2214/AJR.19.21084